US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Kalaris Therapeutics Inc.

3.92

-0.1200-2.97%

Post-market: 4.030.1100+2.81%19:15 EDT

Volume:62.33K

Turnover:246.47K

Market Cap:93.27M

PE:-1.90

High:4.00

Open:3.96

Low:3.86

Close:4.04

52wk High:11.88

52wk Low:3.03

Shares:23.79M

Float Shares:7.23M

Volume Ratio:1.35

T/O Rate:0.86%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-2.0646

EPS(LYR):-2.8500

ROE:-79.91%

ROA:-31.03%

PB:1.62

PE(LYR):-1.38

Loading ...

Overview Company News Filings

Kalaris Therapeutics - TH103 Demonstrates 27- to 53-fold Lower Cmax vs Leading Anti-vegf Agents

THOMSON REUTERS

Kalaris Therapeutics - no Intraocular Inflammation Observed at 2.5 Mg Dose After Process Adjustments

THOMSON REUTERS

Kalaris Therapeutics Reports Positive TH103 Phase 1a Sad Results from Expanded Neovascular Amd Cohorts

THOMSON REUTERS

Kalaris Therapeutics - 41% Retreated at 4 Months or Later, 29% Needed no Additional Treatment in Six Months

THOMSON REUTERS

Kalaris Therapeutics - Enrolling Phase 1B/2 TH103 Study; Initial Data Expected 1H 2027

THOMSON REUTERS

Kalaris Appoints Laurie Keating to Board, Replacing Morana Jovan-embiricos

Press Release: Kalaris Appoints Laurie Keating to Board of Directors

Kalaris Therapeutics says TH103 Phase 1b/2 trial in neovascular AMD is enrolling patients

Kalaris Announces Upcoming Presentation of TH103 Phase 1a Clinical Data at American Society of Retina Specialists; Ph 1B/2 Clinical Trial Actively Enrolling

THOMSON REUTERS

TD Cowen Initiates Kalaris Therapeutics at Buy

MT Newswires Live

Tara Bancroft Initiates Buy on TH103 Developer, Citing Differentiated Wet AMD Profile and Strong Durability Potential in $15B Anti‑VEGF Market

Kalaris Therapeutics Inc : TD Cowen Initiates Coverage With Buy Rating

THOMSON REUTERS

Kalaris Therapeutics to present Phase 1a TH103 data at Clinical Trials at the Summit 2026

Kalaris Therapeutics shareholders elect Ferrara, Hallal, Patterson as Class III directors

CRWV, CVBF, KLRS — Insiders Are Buying These 3 Stocks

Samsara Opportunity Fund buys 244,300 Kalaris Therapeutics shares for $1.18 million

Analysts Are Bullish on Top Healthcare Stocks: Immunome (IMNM), Kalaris Therapeutics (KLRS)

Kalaris Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary

Kalaris Therapeutics Inc Q1 Operating Income USD -11.833 Million

Kalaris net loss widens to $10.9 million in Q1 2026

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://sg.tigeractivity.com/stock/KLRS/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"KLRS","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"KLRS\",,,,,undefined,":{"symbol":"KLRS","market":"US","secType":"STK","nameCN":"Kalaris Therapeutics Inc.","latestPrice":3.92,"timestamp":1788292800000,"preClose":4.04,"halted":0,"volume":62331,"hourTrading":{"tag":"盘后","latestPrice":4.03,"preClose":3.92,"latestTime":"19:15 EDT","volume":157,"amount":628.9955,"timestamp":1788304531772,"change":0.11,"changeRate":0.028061,"amplitude":0.028061},"delay":0,"changeRate":-0.02970297029702973,"floatShares":7230800,"shares":23792278,"eps":-2.064571,"marketStatus":"Not Yet Opened","change":-0.12,"latestTime":"09-01 16:00:00 EDT","open":3.96,"high":4,"low":3.86,"amount":246468.12447510002,"amplitude":0.034653,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-2.064571,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1788336000000},"marketStatusCode":0,"adr":0,"listingDate":1596081600000,"exchange":"NASDAQ","adjPreClose":4.04,"preHourTrading":{"tag":"盘前","latestPrice":3.75,"preClose":4.04,"latestTime":"08:45 EDT","volume":1655,"amount":7158.9810365,"timestamp":1788266743100,"change":-0.29,"changeRate":-0.071782,"amplitude":0.259901},"postHourTrading":{"tag":"盘后","latestPrice":4.03,"preClose":3.92,"latestTime":"19:15 EDT","volume":157,"amount":628.9955,"timestamp":1788304531772,"change":0.11,"changeRate":0.028061,"amplitude":0.028061},"volumeRatio":1.34569},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"KLRS\",,,,,undefined,":{"symbol":"KLRS","floatShares":7230800,"roa":"-31.03%","roe":"-79.91%","lyrEps":-2.849999,"volumeRatio":1.34569,"shares":23792278,"dividePrice":0,"high":4,"amplitude":0.034653,"preClose":4.04,"low":3.86,"week52Low":3.03,"pbRate":"1.62","week52High":11.88,"institutionHeld":0,"latestPrice":3.92,"eps":-2.064571,"divideRate":0,"volume":62331,"delay":0,"ttmEps":-2.064571,"open":3.96,"prevYearClose":8.44,"prevWeekClose":4.03,"prevMonthClose":4.04,"prevQuarterClose":4.07,"fiveDayClose":4.2,"twentyDayClose":4.32,"sixtyDayClose":4.44},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/KLRS\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-08-11","symbol":"KLRS","fiscalQuarterEnding":"2026/06","expectedEps":-0.5,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1786420800000,"reportTimeType":"pre","actualEps":-0.48},{"market":"US","date":"2026-05-12","symbol":"KLRS","fiscalQuarterEnding":"2026/03","expectedEps":-0.52,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1778558400000,"reportTimeType":"pre","actualEps":-0.46},{"market":"US","date":"2026-03-17","symbol":"KLRS","fiscalQuarterEnding":"2025/12","expectedEps":-0.56,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1773720000000,"reportTimeType":"pre","actualEps":-0.44},{"market":"US","date":"2025-11-12","symbol":"KLRS","fiscalQuarterEnding":"2025/09","expectedEps":-0.66,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1762923600000,"reportTimeType":"pre","actualEps":-0.64},{"market":"US","date":"2025-08-13","symbol":"KLRS","fiscalQuarterEnding":"2025/06","expectedEps":-0.51,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1755057600000,"reportTimeType":"pre","actualEps":-0.61}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"KLRS\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"KLRS\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.5,"buy":0.375,"hold":0.125,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.375,"analysts":8,"updateTime":1781582400000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/KLRS\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"KLRS","date":"2026-08-31","current":-1.8987,"percent":0.495822,"low":-3.702314,"twenty":-2.982083,"median":-2.165262,"eighty":-0.855443,"high":-0.558935,"avg":-1.981829,"sd":0.966675,"marketCap":95934073},"quantilePoints":[{"date":"2025-03-28","current":-2.436259,"twenty":-2.629862,"median":-2.463299,"eighty":-2.415709,"marketCap":168508741},{"date":"2025-04-04","current":-2.000923,"twenty":-2.457891,"median":-2.325397,"eighty":-2.168027,"marketCap":138397856},{"date":"2025-04-11","current":-1.976588,"twenty":-2.405434,"median":-2.167216,"eighty":-1.951712,"marketCap":136714639},{"date":"2025-04-17","current":-1.811647,"twenty":-2.361089,"median":-2.042834,"eighty":-1.880868,"marketCap":125306167},{"date":"2025-04-25","current":-1.762976,"twenty":-2.268073,"median":-1.954956,"eighty":-1.818136,"marketCap":121939732},{"date":"2025-05-02","current":-1.581811,"twenty":-2.177762,"median":-1.903581,"eighty":-1.797045,"marketCap":109409116},{"date":"2025-05-09","current":-1.041021,"twenty":-2.168027,"median":-1.865726,"eighty":-1.715927,"marketCap":72004290},{"date":"2025-05-16","current":-0.871644,"twenty":-2.131794,"median":-1.821111,"eighty":-1.36225,"marketCap":66206559},{"date":"2025-05-23","current":-0.696822,"twenty":-2.051217,"median":-1.811647,"eighty":-0.924751,"marketCap":52927842},{"date":"2025-05-30","current":-0.728832,"twenty":-1.996056,"median":-1.784607,"eighty":-0.873072,"marketCap":55359157},{"date":"2025-06-06","current":-0.765766,"twenty":-1.972262,"median":-1.721064,"eighty":-0.77266,"marketCap":58164519},{"date":"2025-06-13","current":-0.679587,"twenty":-1.946844,"median":-1.576403,"eighty":-0.758379,"marketCap":51618673},{"date":"2025-06-20","current":-0.632803,"twenty":-1.914397,"median":-1.295192,"eighty":-0.733756,"marketCap":48065214},{"date":"2025-06-27","current":-0.630341,"twenty":-1.911693,"median":-0.990998,"eighty":-0.714058,"marketCap":47878190},{"date":"2025-07-03","current":-0.615567,"twenty":-1.898714,"median":-0.913935,"eighty":-0.685496,"marketCap":46756045},{"date":"2025-07-11","current":-0.615567,"twenty":-1.891143,"median":-0.871644,"eighty":-0.649054,"marketCap":46756045},{"date":"2025-07-18","current":-0.595869,"twenty":-1.870593,"median":-0.816242,"eighty":-0.639205,"marketCap":45259851},{"date":"2025-07-25","current":-0.699285,"twenty":-1.8614,"median":-0.765766,"eighty":-0.634773,"marketCap":53114867},{"date":"2025-08-01","current":-0.659888,"twenty":-1.83436,"median":-0.758379,"eighty":-0.635266,"marketCap":50122480},{"date":"2025-08-08","current":-0.667275,"twenty":-1.817055,"median":-0.738681,"eighty":-0.635266,"marketCap":50683552},{"date":"2025-08-15","current":-0.558935,"twenty":-1.812188,"median":-0.724523,"eighty":-0.632803,"marketCap":42454488},{"date":"2025-08-22","current":-0.563436,"twenty":-1.811647,"median":-0.714058,"eighty":-0.627879,"marketCap":46007948},{"date":"2025-08-29","current":-0.815379,"twenty":-1.792178,"median":-0.714058,"eighty":-0.615567,"marketCap":66580608},{"date":"2025-09-05","current":-1.067322,"twenty":-1.785689,"median":-0.715289,"eighty":-0.622954,"marketCap":87153267},{"date":"2025-09-12","current":-0.980287,"twenty":-1.771628,"median":-0.728832,"eighty":-0.627879,"marketCap":80046349},{"date":"2025-09-19","current":-1.005482,"twenty":-1.753242,"median":-0.746068,"eighty":-0.629356,"marketCap":82103615},{"date":"2025-09-26","current":-1.092517,"twenty":-1.715927,"median":-0.758379,"eighty":-0.630341,"marketCap":89210533},{"date":"2025-10-03","current":-1.623887,"twenty":-1.652483,"median":-0.783002,"eighty":-0.631818,"marketCap":132600143},{"date":"2025-10-10","current":-1.059306,"twenty":-1.715927,"median":-0.815379,"eighty":-0.632803,"marketCap":86498683},{"date":"2025-10-17","current":-1.097097,"twenty":-1.652483,"median":-0.853303,"eighty":-0.634281,"marketCap":89584582},{"date":"2025-10-24","current":-1.120001,"twenty":-1.598641,"median":-0.878784,"eighty":-0.635266,"marketCap":91454824},{"date":"2025-10-31","current":-1.085645,"twenty":-1.578566,"median":-0.913935,"eighty":-0.635266,"marketCap":88649461},{"date":"2025-11-07","current":-1.083355,"twenty":-1.543053,"median":-0.93448,"eighty":-0.63822,"marketCap":88462437},{"date":"2025-11-14","current":-1.220778,"twenty":-1.513949,"median":-0.991739,"eighty":-0.641667,"marketCap":99683887},{"date":"2025-11-21","current":-2.326591,"twenty":-1.652483,"median":-1.007772,"eighty":-0.642652,"marketCap":129046684},{"date":"2025-11-28","current":-2.104047,"twenty":-1.7661,"median":-1.019224,"eighty":-0.643637,"marketCap":116703088},{"date":"2025-12-05","current":-1.996147,"twenty":-1.811647,"median":-1.04043,"eighty":-0.647085,"marketCap":110718314},{"date":"2025-12-12","current":-2.808768,"twenty":-1.83375,"median":-1.046709,"eighty":-0.650039,"marketCap":155791141},{"date":"2025-12-19","current":-3.513489,"twenty":-1.853956,"median":-1.059878,"eighty":-0.652009,"marketCap":194879195},{"date":"2025-12-26","current":-3.230252,"twenty":-1.885652,"median":-1.065031,"eighty":-0.655456,"marketCap":179169164},{"date":"2026-01-02","current":-2.845859,"twenty":-1.914397,"median":-1.075338,"eighty":-0.657426,"marketCap":157848407},{"date":"2026-01-09","current":-2.785165,"twenty":-1.996147,"median":-1.083355,"eighty":-0.657426,"marketCap":154481972},{"date":"2026-01-16","current":-2.987477,"twenty":-2.104047,"median":-1.089081,"eighty":-0.657426,"marketCap":165703423},{"date":"2026-01-23","current":-3.29769,"twenty":-2.164782,"median":-1.092517,"eighty":-0.659396,"marketCap":182909648},{"date":"2026-01-30","current":-3.102121,"twenty":-2.196152,"median":-1.097097,"eighty":-0.661858,"marketCap":172062245},{"date":"2026-02-06","current":-2.815512,"twenty":-2.367922,"median":-1.114275,"eighty":-0.662351,"marketCap":156165190},{"date":"2026-02-13","current":-3.02794,"twenty":-2.502772,"median":-1.122292,"eighty":-0.662351,"marketCap":167947713},{"date":"2026-02-20","current":-3.702314,"twenty":-2.785165,"median":-1.136034,"eighty":-0.665305,"marketCap":205352549},{"date":"2026-02-27","current":-3.560695,"twenty":-2.810117,"median":-1.145196,"eighty":-0.674662,"marketCap":197497534},{"date":"2026-03-06","current":-3.262285,"twenty":-2.841832,"median":-1.152067,"eighty":-0.679587,"marketCap":180945894},{"date":"2026-03-13","current":-3.092005,"twenty":-2.933528,"median":-1.165399,"eighty":-0.681064,"marketCap":171501173},{"date":"2026-03-20","current":-2.932075,"twenty":-2.973316,"median":-1.284909,"eighty":-0.685003,"marketCap":127363466},{"date":"2026-03-27","current":-3.072027,"twenty":-2.992198,"median":-1.357057,"eighty":-0.692882,"marketCap":133442723},{"date":"2026-04-02","current":-3.132729,"twenty":-3.014452,"median":-1.458617,"eighty":-0.697807,"marketCap":136079478},{"date":"2026-04-10","current":-3.203987,"twenty":-3.059472,"median":-1.52082,"eighty":-0.701747,"marketCap":139174799},{"date":"2026-04-17","current":-3.478464,"twenty":-3.075922,"median":-1.602849,"eighty":-0.708887,"marketCap":151097516},{"date":"2026-04-24","current":-3.219822,"twenty":-3.095853,"median":-1.746752,"eighty":-0.714058,"marketCap":139862648},{"date":"2026-05-01","current":-2.913675,"twenty":-3.10064,"median":-1.776394,"eighty":-0.714058,"marketCap":126564232},{"date":"2026-05-08","current":-2.725961,"twenty":-3.095853,"median":-1.811647,"eighty":-0.715043,"marketCap":118410298},{"date":"2026-05-15","current":-2.72166,"twenty":-3.087959,"median":-1.820952,"eighty":-0.717998,"marketCap":120019759},{"date":"2026-05-22","current":-2.669521,"twenty":-3.080541,"median":-1.83767,"eighty":-0.723661,"marketCap":117720529},{"date":"2026-05-29","current":-2.700804,"twenty":-3.078518,"median":-1.841041,"eighty":-0.729817,"marketCap":119100067},{"date":"2026-06-05","current":-2.429681,"twenty":-3.07722,"median":-1.863022,"eighty":-0.734741,"marketCap":107144076},{"date":"2026-06-12","current":-2.352359,"twenty":-3.072027,"median":-1.890061,"eighty":-0.741636,"marketCap":103734332},{"date":"2026-06-18","current":-2.45487,"twenty":-3.072027,"median":-1.911693,"eighty":-0.753455,"marketCap":108254864},{"date":"2026-06-26","current":-2.319987,"twenty":-3.071774,"median":-1.965772,"eighty":-0.758379,"marketCap":102306795},{"date":"2026-07-02","current":-2.44408,"twenty":-3.063682,"median":-1.990247,"eighty":-0.758379,"marketCap":107779019},{"date":"2026-07-10","current":-2.422498,"twenty":-3.057285,"median":-2.077072,"eighty":-0.760349,"marketCap":106827328},{"date":"2026-07-17","current":-2.487242,"twenty":-3.052473,"median":-2.104047,"eighty":-0.764781,"marketCap":109682401},{"date":"2026-07-24","current":-2.114965,"twenty":-3.046817,"median":-2.114965,"eighty":-0.793344,"marketCap":93265729},{"date":"2026-07-31","current":-1.877571,"twenty":-3.035018,"median":-2.104047,"eighty":-0.807625,"marketCap":82797127},{"date":"2026-08-07","current":-2.260639,"twenty":-3.007709,"median":-2.112878,"eighty":-0.814247,"marketCap":99689644},{"date":"2026-08-14","current":-2.08558,"twenty":-2.992198,"median":-2.117831,"eighty":-0.818113,"marketCap":92314038},{"date":"2026-08-21","current":-2.215768,"twenty":-2.988826,"median":-2.131838,"eighty":-0.837815,"marketCap":98076521},{"date":"2026-08-28","current":-2.205011,"twenty":-2.983431,"median":-2.16316,"eighty":-0.854016,"marketCap":97600422},{"date":"2026-08-31","current":-2.167365,"twenty":-2.982083,"median":-2.165262,"eighty":-0.855443,"marketCap":95934073}],"updateTime":1788330950752},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"KLRS\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2652485407","title":"Kalaris Therapeutics - TH103 Demonstrates 27- to 53-fold Lower Cmax vs Leading Anti-vegf Agents","url":"https://stock-news.laohu8.com/highlight/detail?id=2652485407","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2652485407?lang=en_us&edition=fundamental","pubTime":"2026-07-17 19:00","pubTimestamp":1784286000,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260717:nTUA2DPYTJ:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","KLRS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652407161","title":"Kalaris Therapeutics - no Intraocular Inflammation Observed at 2.5 Mg Dose After Process Adjustments","url":"https://stock-news.laohu8.com/highlight/detail?id=2652407161","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2652407161?lang=en_us&edition=fundamental","pubTime":"2026-07-17 19:00","pubTimestamp":1784286000,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260717:nTUA2DPYTJ:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["KLRS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652407132","title":"Kalaris Therapeutics Reports Positive TH103 Phase 1a Sad Results from Expanded Neovascular Amd Cohorts","url":"https://stock-news.laohu8.com/highlight/detail?id=2652407132","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2652407132?lang=en_us&edition=fundamental","pubTime":"2026-07-17 19:00","pubTimestamp":1784286000,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260717:nTUA2DPYTJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["KLRS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652172407","title":"Kalaris Therapeutics - 41% Retreated at 4 Months or Later, 29% Needed no Additional Treatment in Six Months","url":"https://stock-news.laohu8.com/highlight/detail?id=2652172407","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2652172407?lang=en_us&edition=fundamental","pubTime":"2026-07-17 19:00","pubTimestamp":1784286000,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260717:nTUA2DPYTJ:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","KLRS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652071344","title":"Kalaris Therapeutics - Enrolling Phase 1B/2 TH103 Study; Initial Data Expected 1H 2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2652071344","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2652071344?lang=en_us&edition=fundamental","pubTime":"2026-07-17 19:00","pubTimestamp":1784286000,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260717:nTUA2DPYTJ:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["KLRS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649367911","title":"Kalaris Appoints Laurie Keating to Board, Replacing Morana Jovan-embiricos","url":"https://stock-news.laohu8.com/highlight/detail?id=2649367911","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649367911?lang=en_us&edition=fundamental","pubTime":"2026-07-07 04:06","pubTimestamp":1783368368,"startTime":"0","endTime":"0","summary":"Kalaris appoints Laurie Keating to board, replacing Morana Jovan-EmbiricosKalaris Therapeutics named Laurie Keating to its board, effective Aug. 1, 2026.Director Morana Jovan-Embiricos will step down ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260706:nNDL5PG1ny:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0109394709.USD","LU0889565916.HKD","BK4539","IE00B3QW5Z07.USD","LU2210149790.SGD","IE00B64PRP62.GBP","BK4585","BK4588","BK4112","ALNY","IE00BN0W2W23.USD","BK4139","IMRX","LU0114720955.EUR","BK4563","LU2095319765.USD","KLRS","LU0320765992.SGD","IE00BKPKM429.USD","SG9999014013.SGD","LU0314104364.USD","LU2210150020.SGD","PBE","LU0882574055.USD","IE00BN0W2T93.GBP","BCDF","SG9999014039.USD","SG9999014005.SGD","NDAQ","IE00BGHQF748.EUR","SG9999014021.USD","IE00BN0W2V16.EUR","BK4548"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649467992","title":"Press Release: Kalaris Appoints Laurie Keating to Board of Directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2649467992","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649467992?lang=en_us&edition=fundamental","pubTime":"2026-07-07 04:05","pubTimestamp":1783368300,"startTime":"0","endTime":"0","summary":"BERKELEY HEIGHTS, N.J., July 06, 2026 (GLOBE NEWSWIRE) -- Kalaris Therapeutics, Inc. (Nasdaq: KLRS) (\"Kalaris\"), a clinical-stage biopharmaceutical company dedicated to the development and commerciali","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KLRS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645835486","title":"Kalaris Therapeutics says TH103 Phase 1b/2 trial in neovascular AMD is enrolling patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2645835486","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645835486?lang=en_us&edition=fundamental","pubTime":"2026-06-23 20:00","pubTimestamp":1782216059,"startTime":"0","endTime":"0","summary":"Kalaris Therapeutics set a July 17, 2026 ASRS presentation for Phase 1a first-in-human data on TH103 in treatment-nave wet AMD.Results have not yet been presented; the update is positioned as an early read on safety and initial clinical activity.A Phase 1b/2 multiple-ascending-dose trial in neovascular AMD is actively enrolling and dosing, supporting dose selection for a potential Phase 3 program.Initial Phase 1b/2 data are expected in 1H 2027, a key catalyst for TH103’s development timeline.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260623:nNDL1c14RF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BN0W2V16.EUR","SG9999014039.USD","BK4585","LU0314104364.USD","IE00B3QW5Z07.USD","SG9999014013.SGD","IE00B64PRP62.GBP","LU2210150020.SGD","NDAQ","SG9999014005.SGD","BK4588","IE00BGHQF748.EUR","KLRS","BK4112","IE00BKPKM429.USD","SG9999014021.USD","IE00BN0W2T93.GBP","LU2210149790.SGD","LU2095319765.USD","IE00BN0W2W23.USD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645835480","title":"Kalaris Announces Upcoming Presentation of TH103 Phase 1a Clinical Data at American Society of Retina Specialists; Ph 1B/2 Clinical Trial Actively Enrolling","url":"https://stock-news.laohu8.com/highlight/detail?id=2645835480","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645835480?lang=en_us&edition=fundamental","pubTime":"2026-06-23 20:00","pubTimestamp":1782216005,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260623:nTUA5KJHFF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","KLRS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643272511","title":"TD Cowen Initiates Kalaris Therapeutics at Buy","url":"https://stock-news.laohu8.com/highlight/detail?id=2643272511","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643272511?lang=en_us&edition=fundamental","pubTime":"2026-06-15 18:05","pubTimestamp":1781517928,"startTime":"0","endTime":"0","summary":"Kalaris Therapeutics (KRLS) has an average rating of buy and mean price target of $19, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major b","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["TD","BK4585","KLRS","LENZ","BK4127","BK4539","COWN","BK4207","BK4139","BK4007","BK4566"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643027474","title":"Tara Bancroft Initiates Buy on TH103 Developer, Citing Differentiated Wet AMD Profile and Strong Durability Potential in $15B Anti‑VEGF Market","url":"https://stock-news.laohu8.com/highlight/detail?id=2643027474","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643027474?lang=en_us&edition=fundamental","pubTime":"2026-06-15 17:59","pubTimestamp":1781517543,"startTime":"0","endTime":"0","summary":"Tara Bancroft, an analyst from TD Cowen, has initiated a new Buy rating on Kalaris Therapeutics (KLRS). Tara Bancroft has given his Buy rating due ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/tara-bancroft-initiates-buy-on-th103-developer-citing-differentiated-wet-amd-profile-and-strong-durability-potential-in-15b-antivegf-market-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/tara-bancroft-initiates-buy-on-th103-developer-citing-differentiated-wet-amd-profile-and-strong-durability-potential-in-15b-antivegf-market-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","KLRS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643274806","title":"Kalaris Therapeutics Inc : TD Cowen Initiates Coverage With Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2643274806","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2643274806?lang=en_us&edition=fundamental","pubTime":"2026-06-15 17:41","pubTimestamp":1781516493,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260615:nFWN42K0DE:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","KLRS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642988882","title":"Kalaris Therapeutics to present Phase 1a TH103 data at Clinical Trials at the Summit 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2642988882","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642988882?lang=en_us&edition=fundamental","pubTime":"2026-06-12 20:04","pubTimestamp":1781265841,"startTime":"0","endTime":"0","summary":"Kalaris Therapeutics will present Phase 1a single-ascending-dose data for TH103 at Clinical Trials at the Summit 2026 on June 13, 2026.Readout covers treatment-nave patients with neovascular age-related macular degeneration, a key indication for the company’s lead retinal program.Presentation is scheduled for 7:09 a.m. PDT in Las Vegas, within a session focused on novel mechanisms of action.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kalaris Therapeutics Inc. published the original content used to generate this news brief on June 12, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260612:nNDL9R1gzv:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KLRS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641669162","title":"Kalaris Therapeutics shareholders elect Ferrara, Hallal, Patterson as Class III directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2641669162","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2641669162?lang=en_us&edition=fundamental","pubTime":"2026-06-05 04:10","pubTimestamp":1780603848,"startTime":"0","endTime":"0","summary":"Kalaris Therapeutics held its annual shareholder meeting on June 3, 2026.Shareholders backed the board’s slate of Class III director nominees for three-year terms expiring at the 2029 annual meeting.Investors voted to hold future advisory votes on executive pay every year; the board indicated it intends to follow that schedule.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kalaris Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 04, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260604:nNDL7Rh0VK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KLRS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638555059","title":"CRWV, CVBF, KLRS — Insiders Are Buying These 3 Stocks","url":"https://stock-news.laohu8.com/highlight/detail?id=2638555059","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638555059?lang=en_us&edition=fundamental","pubTime":"2026-05-25 22:30","pubTimestamp":1779719402,"startTime":"0","endTime":"0","summary":"Insider buying often attracts attention because company executives typically understand their business better than most investors. When insiders bu...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/crwv-cvbf-klrs-insiders-are-buying-these-3-stocks?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/crwv-cvbf-klrs-insiders-are-buying-these-3-stocks?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CVBF","BK4139","BK4211","KLRS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637340618","title":"Samsara Opportunity Fund buys 244,300 Kalaris Therapeutics shares for $1.18 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2637340618","media":"Reuters","labels":["insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637340618?lang=en_us&edition=fundamental","pubTime":"2026-05-23 07:48","pubTimestamp":1779493694,"startTime":"0","endTime":"0","summary":"Kalaris Therapeutics director and 10% owner Srinivas Akkaraju reported an indirect purchase of 244,300 common shares at USD 4.83.Samsara Opportunity Fund’s indirect stake rose to 2,224,147 shares.Samsara BioCapital reported an in-kind distribution that reduced its indirect holding by 66,906 shares to 10,657,028.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kalaris Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 22, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260522:nNDL7gG0Q7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Samsara Opportunity Fund buys 244,300 Kalaris Therapeutics shares for $1.18 million","news_tag":"insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","KLRS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635225276","title":"Analysts Are Bullish on Top Healthcare Stocks: Immunome (IMNM), Kalaris Therapeutics (KLRS)","url":"https://stock-news.laohu8.com/highlight/detail?id=2635225276","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635225276?lang=en_us&edition=fundamental","pubTime":"2026-05-13 05:50","pubTimestamp":1778622605,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Immunome (IMNM) and Kalaris Therapeutics (KLRS) with...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-top-healthcare-stocks-immunome-imnm-kalaris-therapeutics-klrs-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-top-healthcare-stocks-immunome-imnm-kalaris-therapeutics-klrs-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4581","BK4563","BK4585","BK4588","BLSG","KLRS","LABU","BK4112","BK4137","BLSX","BK4139","LU0128526141.USD","XBI","LU0029874061.USD","IMNM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634245978","title":"Kalaris Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2634245978","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634245978?lang=en_us&edition=fundamental","pubTime":"2026-05-12 23:53","pubTimestamp":1778601205,"startTime":"0","endTime":"0","summary":"Kalaris Therapeutics Inc reports results for the quarter ended March 31 - Earnings SummaryKalaris Therapeutics Inc KLRS.OQ reported a quarterly adjusted loss of 46 cents per share for the quarter ende","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260512:nL8N41P2IZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KLRS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634219933","title":"Kalaris Therapeutics Inc Q1 Operating Income USD -11.833 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2634219933","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634219933?lang=en_us&edition=fundamental","pubTime":"2026-05-12 20:14","pubTimestamp":1778588046,"startTime":"0","endTime":"0","summary":"May 12 (Reuters) - Kalaris Therapeutics Inc Q1 operating expenses USD 11.833 million.:  ((Reuters Investor Briefs; email: reutersinvestor.briefs@thomsonreuters.com))  Source Date/Time = 12-MAY-202610:25:00.083 GMT","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260512:nRSDbq9hPY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KLRS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634216088","title":"Kalaris net loss widens to $10.9 million in Q1 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2634216088","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634216088?lang=en_us&edition=fundamental","pubTime":"2026-05-12 20:04","pubTimestamp":1778587479,"startTime":"0","endTime":"0","summary":"Kalaris Therapeutics posted a Q1 net loss of USD 10.9 million, widening from USD 10.2 million a year earlier.Research and development expense rose to USD 7.6 million from USD 6 million, while general and administrative expense held at USD 4.3 million.Cash, cash equivalents and marketable securities fell to USD 104.9 million as of March 31, 2026 from USD 118 million at year-end 2025.Patient screening began in Phase 1b/2 multiple ascending dose study of TH103 in neovascular age-related macular degeneration, with preliminary data expected in 1H 2027.Planned Phase 3 trials remain on track for 2027 year-end initiation, with cash expected to fund operations into Q4 2027.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260512:nNDL850Cgg:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BN0W2V16.EUR","NDAQ","BK4585","IE00BGHQF748.EUR","IE00BN0W2T93.GBP","LU0314104364.USD","IE00BKPKM429.USD","IE00B64PRP62.GBP","BK4112","LU2095319765.USD","BK4139","SG9999014039.USD","SG9999014021.USD","BK4588","SG9999014013.SGD","SG9999014005.SGD","IE00B3QW5Z07.USD","LU2210150020.SGD","LU2210149790.SGD","KLRS","IE00BN0W2W23.USD"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":2,"totalSize":51,"code":"91000000","status":"200"}]}}